Overview of Autobio Strategic Cooperation Overview in 2021

The growth of international IVD top enterprises is a history of mergers and acquisitions and cooperation. If there is no strategic cooperation between enterprises, it is difficult to form tycoon.

As one of the top local in vitro diagnostic companies, Autobio will actively carry out a variety of strategic cooperation in 2021.

On March 8, Autobio and Sekisui Medical Technology announced that they have reached a strategic cooperation in the field of coagulation detection.

On April 8, Mobidiag Oy, the shareholding company of Autobio, signed an equity sale agreement with Hologic, Inc., planning to sell all of its shares to Hologic, Inc., of which Autobio holds 7.63% of Mobidiag Oy for approximately 4609 Ten thousand euros for sale.

On April 13, Autobio and Henan Infectious Disease Hospital held a strategic cooperation signing ceremony to jointly promote the integrated development of industry, university and research.

On July 17, Autobio held a strategic cooperation with Linzhou People's Hospital to jointly build a high-quality standardized Linzhou Regional Medical Laboratory Center.

On July 25, Autobio established a strategic partnership with SysCan Medtech to provide complete blood coagulation testing products and service solutions for the medical laboratory field.

The IVD industry is a community. Under the normalization of the epidemic situation, local IVD companies should continue to strengthen strategic cooperation, realize the complementarity of product lines and market resources, improve research and development capabilities and professional quality, so as to achieve the healthy and sustainable development of the entire IVD industry.